Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 5Phase 3 4Phase 1/2 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 1

Conditions

Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Malignancies 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × sitravatinib × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

NCT03906071 2025-10-21

SAPPHIRE

Mirati Therapeutics Inc.

Phase 3 Completed
577 enrolled 22 charts
Thoracic

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT04921358 2025-06-29

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

BeiGene

Phase 3 Terminated
377 enrolled 22 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05564338 2023-06-07

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

BeiGene

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡